PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Clinical trial NCT07472153 · RECRUITING

Trial details

NCT number: NCT07472153
Sponsor: N.N. Alexandrov National Cancer Centre
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Metastatic Cervical Cancer Persistent Cervical Cancer Recurrent Cervical Cancer

Start date: 2025-07-01
Primary completion: 2030-06-30
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.